Cargando…

Efficacy of Acetylshikonin in Preventing Obesity and Hepatic Steatosis in db/db Mice

Zicao (Lithospermum erythrorhizon) has been used in clinics as a traditional Chinese medicine for thousands of years. Acetylshikonin (AS) is the main ingredient of Zicao, Xinjiang, China. The objective of this study was to investigate the anti-obesity and anti-nonalcoholic fatty liver disease (NAFLD...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Mei-Ling, He, Yu, Li, Qi-Sen, Zhu, Bang-Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6273802/
https://www.ncbi.nlm.nih.gov/pubmed/27483220
http://dx.doi.org/10.3390/molecules21080976
_version_ 1783377471508316160
author Su, Mei-Ling
He, Yu
Li, Qi-Sen
Zhu, Bang-Hao
author_facet Su, Mei-Ling
He, Yu
Li, Qi-Sen
Zhu, Bang-Hao
author_sort Su, Mei-Ling
collection PubMed
description Zicao (Lithospermum erythrorhizon) has been used in clinics as a traditional Chinese medicine for thousands of years. Acetylshikonin (AS) is the main ingredient of Zicao, Xinjiang, China. The objective of this study was to investigate the anti-obesity and anti-nonalcoholic fatty liver disease (NAFLD) efficacy of AS in a model of spontaneous obese db/db mice. Mice were divided into Wild Type (WT) groups and db/db groups, which received no treatment or treatment with 100 mg/kg/day clenbuterol (CL) hydrochloride or 540 mg/kg/day AS by oral gavage for eight weeks. The results provided the evidence that AS prevented obesity and NAFLD including reduction in body weight, food efficiency ratio, serum triglyceride (TG) and free fatty acid (FFA) levels in db/db mice. Administration of AS markedly suppressed the levels of hepatic alanine aminotransferase (ALT), aspartate aminotransferase (AST) and pro-inflammatory cytokines in treated groups when compared with that of db/db groups. Further investigation of the lipid synthesis-related protein using Western blotting revealed that hepatic protein expression of sterol regulatory element-binding protein-1 (SREBP-1), fatty acid synthetase (FAS) and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) were significantly downregulated by AS treatment. These findings suggest that AS exerts anti-obesity and anti-NAFLD effects through the regulation of lipid metabolism and anti-inflammatory effects.
format Online
Article
Text
id pubmed-6273802
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62738022018-12-28 Efficacy of Acetylshikonin in Preventing Obesity and Hepatic Steatosis in db/db Mice Su, Mei-Ling He, Yu Li, Qi-Sen Zhu, Bang-Hao Molecules Article Zicao (Lithospermum erythrorhizon) has been used in clinics as a traditional Chinese medicine for thousands of years. Acetylshikonin (AS) is the main ingredient of Zicao, Xinjiang, China. The objective of this study was to investigate the anti-obesity and anti-nonalcoholic fatty liver disease (NAFLD) efficacy of AS in a model of spontaneous obese db/db mice. Mice were divided into Wild Type (WT) groups and db/db groups, which received no treatment or treatment with 100 mg/kg/day clenbuterol (CL) hydrochloride or 540 mg/kg/day AS by oral gavage for eight weeks. The results provided the evidence that AS prevented obesity and NAFLD including reduction in body weight, food efficiency ratio, serum triglyceride (TG) and free fatty acid (FFA) levels in db/db mice. Administration of AS markedly suppressed the levels of hepatic alanine aminotransferase (ALT), aspartate aminotransferase (AST) and pro-inflammatory cytokines in treated groups when compared with that of db/db groups. Further investigation of the lipid synthesis-related protein using Western blotting revealed that hepatic protein expression of sterol regulatory element-binding protein-1 (SREBP-1), fatty acid synthetase (FAS) and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) were significantly downregulated by AS treatment. These findings suggest that AS exerts anti-obesity and anti-NAFLD effects through the regulation of lipid metabolism and anti-inflammatory effects. MDPI 2016-07-28 /pmc/articles/PMC6273802/ /pubmed/27483220 http://dx.doi.org/10.3390/molecules21080976 Text en © 2016 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Su, Mei-Ling
He, Yu
Li, Qi-Sen
Zhu, Bang-Hao
Efficacy of Acetylshikonin in Preventing Obesity and Hepatic Steatosis in db/db Mice
title Efficacy of Acetylshikonin in Preventing Obesity and Hepatic Steatosis in db/db Mice
title_full Efficacy of Acetylshikonin in Preventing Obesity and Hepatic Steatosis in db/db Mice
title_fullStr Efficacy of Acetylshikonin in Preventing Obesity and Hepatic Steatosis in db/db Mice
title_full_unstemmed Efficacy of Acetylshikonin in Preventing Obesity and Hepatic Steatosis in db/db Mice
title_short Efficacy of Acetylshikonin in Preventing Obesity and Hepatic Steatosis in db/db Mice
title_sort efficacy of acetylshikonin in preventing obesity and hepatic steatosis in db/db mice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6273802/
https://www.ncbi.nlm.nih.gov/pubmed/27483220
http://dx.doi.org/10.3390/molecules21080976
work_keys_str_mv AT sumeiling efficacyofacetylshikonininpreventingobesityandhepaticsteatosisindbdbmice
AT heyu efficacyofacetylshikonininpreventingobesityandhepaticsteatosisindbdbmice
AT liqisen efficacyofacetylshikonininpreventingobesityandhepaticsteatosisindbdbmice
AT zhubanghao efficacyofacetylshikonininpreventingobesityandhepaticsteatosisindbdbmice